Literature DB >> 171282

Collagenase in scleroderma.

A H Brady.   

Abstract

Collagenase activity was measured by direct assay in skins from 12 patients afflicted with systemic sclerosis. In seven of those cases where extensive involvement of the forearm and trunk skin existed, collagenase activity of the involved skin was minimal or absent. Moreover, in the same patient, regions of marked skin involvement (e.g., forearm) showed no collagenase activity, when clinically uninvolved areas (thigh) exhibited normal or nearly normal levels of enzyme activity. In other patients where clinical symptoms were systemic and not associated significantly with the skin, collagenase activity approximated normal levels. Measurements of collagenase activity and tensile strength in another condition (basal cell carcinoma) that includes changes in mechanical properties of skin that any be regarded as the opposite end of the spectrum from those of sclerodermatous skin support a general correlation between collagenase activity and tensile strength. These studies indicate that the major defect responsible for the hidebound skin lesions of scleroderma may be decreased collagenase activity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 171282      PMCID: PMC301981          DOI: 10.1172/JCI108194

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  ISOTONIC AND ISOMETRIC THERMAL CONTRACTION OF HUMAN DERMIS. 3. SCLERODERMA AND CICATRIZING LESIONS.

Authors:  D M RASMUSSEN; K G WAKIM; R K WINKELMANN
Journal:  J Invest Dermatol       Date:  1964-11       Impact factor: 8.551

2.  THE COLLAGEN IN SCLERODERMA.

Authors:  R FLEISCHMAJER
Journal:  Arch Dermatol       Date:  1964-03

3.  AMINO-ACID COMPOSITION OF HUMAN DERMAL COLLAGEN.

Authors:  R FLEISCHMAJER; L FISHMAN
Journal:  Nature       Date:  1965-01-16       Impact factor: 49.962

4.  Pathologic observations concerning the cutaneous lesion of progressive systemic sclerosis: an electron microscopic histochemical and immunohistochemical study.

Authors:  E R FISHER; G P RODNAN
Journal:  Arthritis Rheum       Date:  1960-12

5.  Effect of collagenolytic activity in basal cell epithelioma of the skin on reconstituted collagen and physical properties and kinetics of the crude enzyme.

Authors:  Y Yamanishi; M K Dabbous; K Hashimoto
Journal:  Cancer Res       Date:  1972-11       Impact factor: 12.701

6.  Mammalian collagenase: direct demonstration in homogenates of involuting rat uterus.

Authors:  J N Ryan; J F Woessner
Journal:  Biochem Biophys Res Commun       Date:  1971-07-02       Impact factor: 3.575

7.  Biosynthesis and maturation of skin collagen in scleroderma, and effect of D-penicillamine.

Authors:  C M Herbert; K A Lindberg; M I Jayson; A J Bailey
Journal:  Lancet       Date:  1974-02-09       Impact factor: 79.321

8.  Glycosaminoglycans in scleroderma and scleredema.

Authors:  R Fleischmajer; J S Perlish
Journal:  J Invest Dermatol       Date:  1972-03       Impact factor: 8.551

9.  A study of carbohydrate metabolism in scleroderma. Preliminary report.

Authors:  R Fleischmajer; G Faludi
Journal:  J Invest Dermatol       Date:  1969-04       Impact factor: 8.551

10.  Human skin collagenase: localization and distribution in normal human skin.

Authors:  A Z Eisen
Journal:  J Invest Dermatol       Date:  1969-05       Impact factor: 8.551

View more
  11 in total

Review 1.  Penicillamine types in the sclerodermas.

Authors:  T H Tio
Journal:  Proc R Soc Med       Date:  1977

2.  Plasma concentration of total and transformed alpha 2-macroglobulin in systemic sclerosis.

Authors:  G Birkenmeier; R Frank
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

3.  Pathology of collagen degradation. A review.

Authors:  R Pérez-Tamayo
Journal:  Am J Pathol       Date:  1978-08       Impact factor: 4.307

4.  Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis.

Authors:  Remedios Castello-Cros; Diana Whitaker-Menezes; Alex Molchansky; George Purkins; Louis J Soslowsky; David P Beason; Federica Sotgia; Renato V Iozzo; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

5.  Cell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation.

Authors:  Michael J Podolsky; Deepti Gupta; Arnold Ha; Ryan Ta; Amin Khalifeh-Soltani; William McKleroy; Ritwik Datta; Dean Sheppard; Kamran Atabai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-05-24       Impact factor: 5.464

6.  Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis.

Authors:  M Selman; M Montaño; C Ramos; R Chapela
Journal:  Thorax       Date:  1986-05       Impact factor: 9.139

7.  Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture.

Authors:  J Uitto; E A Bauer; A Z Eisen
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

Review 8.  Extracellular matrix in lung development, homeostasis and disease.

Authors:  Yong Zhou; Jeffrey C Horowitz; Alexandra Naba; Namasivayam Ambalavanan; Kamran Atabai; Jenna Balestrini; Peter B Bitterman; Richard A Corley; Bi-Sen Ding; Adam J Engler; Kirk C Hansen; James S Hagood; Farrah Kheradmand; Qing S Lin; Enid Neptune; Laura Niklason; Luis A Ortiz; William C Parks; Daniel J Tschumperlin; Eric S White; Harold A Chapman; Victor J Thannickal
Journal:  Matrix Biol       Date:  2018-03-08       Impact factor: 11.583

Review 9.  Mechanisms for the Resolution of Organ Fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Physiology (Bethesda)       Date:  2019-01-01

Review 10.  Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis.

Authors:  William McKleroy; Ting-Hein Lee; Kamran Atabai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-05       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.